Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trifluperidol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 15/20 | 0.64 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.64 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.64 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | THPO | P40225 | 2/20 | 0.73 |
| ▸ | MTOR | P42345 | 2/20 | 0.73 |
| ▸ | EBP | Q15125 | 2/20 | 0.73 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.64 |
| ▸ | HTR1A | P08908 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluperidol SCHEMBL28086762 | 0.91 | ABCB11 (0.88) | ABCB11CYP3A4CYP2D6TSHRTHPO | |
| Haloperidol SCHEMBL4177109 | 0.90 | DRD2 (0.80) | ABCB11CYP3A4CYP2D6TSHRTHPO | |
| Haloperidol SCHEMBL41057 | 0.90 | DRD2 (0.80) | ABCB11CYP3A4CYP2D6TSHRTHPO | |
| Haloperidol SCHEMBL19463557 | 0.90 | DRD2 (0.80) | ABCB11CYP3A4CYP2D6TSHRTHPO | |
| Haloperidol SCHEMBL28595609 | 0.89 | DRD2 (0.78) | ABCB11CYP3A4CYP2D6TSHRTHPO | |
| Trifluperidol SCHEMBL29710906 | 0.85 | CYP3A4 (1.00) | ABCB11CYP3A4CYP2D6TSHRTHPO | |
| Trifluperidol SCHEMBL120862 | 0.85 | CYP3A4 (1.00) | ABCB11CYP3A4CYP2D6TSHRTHPO | |
| Haloperidol SCHEMBL10392879 | 0.85 | DRD2 (0.72) | ABCB11CYP3A4CYP2D6TSHRTHPO | |
| Haloperidol SCHEMBL5452448 | 0.85 | DRD2 (0.72) | ABCB11CYP3A4CYP2D6TSHRTHPO | |
| Haloperidol SCHEMBL10392880 | 0.85 | DRD2 (0.72) | ABCB11CYP3A4CYP2D6TSHRTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106064-A1 | Butyrophenones and sigma-1 receptor antagonists protect against oxidative-stress | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH (US) | 2006-05-18 | — | — | US | claimed |
| WO-2006050511-A2 | BUTYROPHENOMENES AND SIGMA-1 RECEPTOR ANTAGONISTS PROTECT AGAINST OXIDATIVES-STRESS | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH (US) | 2006-05-11 | — | — | WO | claimed |
| US-20090156637-A1 | BUTYROPHENONES AND SIGMA-1 RECEPTOR ANTAGONISTS PROTECT AGAINST OXIDATIVE-STRESS | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER OF FORT WORTH (US) | 2009-06-18 | — | — | US | disclosed |
| US-20060106064-A1 | Butyrophenones and sigma-1 receptor antagonists protect against oxidative-stress | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH (US) | 2006-05-18 | — | — | US | disclosed |
| WO-2006050511-A2 | BUTYROPHENOMENES AND SIGMA-1 RECEPTOR ANTAGONISTS PROTECT AGAINST OXIDATIVES-STRESS | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156637-A1 | BUTYROPHENONES AND SIGMA-1 RECEPTOR ANTAGONISTS PROTECT AGAINST OXIDATIVE-STRESS | SIGMAR1, OPRK1, OPRL1 | DRD2 141/4885DRD4 213/4885DRD3 120/4885 |
| US-20060106064-A1 | Butyrophenones and sigma-1 receptor antagonists protect against oxidative-stress | SIGMAR1, OPRK1, OPRL1 | DRD2 141/4885DRD4 213/4885DRD3 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.